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Serum OX40 ligand: a potential marker of atopic dermatitis disease 
severity in children  
 
INTRODUCTION 
The tumor necrosis factor receptor (TNFR) family 
consists of a number of type I transmembrane 
glycoproteins characterized by homologous 
cysteine-rich domains in their extracellular region. 
The intracellular parts of these proteins vary in size 
and structure, corresponding to the wide array of 
functions of TNFR proteins, ranging from 
regulation of cell activation and differentiation to 
induction of cell death. Twenty-two TNFR family 
members have been identified, including TNFR1, 
TNFR2, the low-affinity nerve growth factor 
receptor, CD27, CD30, CD40, CD95 (Fas), and 
CD134 (OX40). Except for the ligands of the low-
affinity nerve growth factor receptor, the ligands of 
TNFR proteins form the family of TNF-related 
proteins. Most TNF family members can be 
expressed as type II transmembrane receptors, and 
some of these proteins mediate signal transduction 
via their intracellular domain. Several members of 
the TNFR family (e.g., CD95, TNFR1, and 
TNFR2) and the TNF family (e.g., TNF-α, CD40 
ligand, and CD95 ligand) can be produced as 
Original article 
Background: OX40 ligand (OX40L) and OX40 are members of the tumor 
necrosis factor (TNF) and TNF receptor (TNFR) super families respectively. 
Recent studies have indicated the critical involvement of OX40/OX40L 
interaction in the pathogenesis of atopic dermatitis. To our knowledge, no 
data could be cited in literature concerning OX40L levels in serum or in 
other biological fluids of atopic dermatitis children.  
Objective: This study was done to explore the expression of OX40L in the 
serum of atopic dermatitis children with respect to disease activity and 
severity. 
Methods: This follow-up, case-control longitudinal study was conducted on 
64 children as a stratified non-random sample; 34 with atopic dermatitis 
and 30 healthy children. Serum concentrations of OX40L were measured by 
sandwich enzyme immunoassay. The severity of atopic dermatitis was 
assessed according to the Leicester Sign Score (LSS), Simple Scoring System 
(SSS), Scoring Atopic Dermatitis (SCORAD) index, and Objective SCORAD. 
Results: Serum OX40L levels (pg/ml) in atopic dermatitis patients were 
significantly elevated as compared to controls (176.6 ± 45.9) whether during 
flare (1007 ± 241.5) or quiescence (699 ± 198.5). There were significant 
positive correlations between serum OX40L levels and each of the LSS, SSS 
and SCORAD indices of atopic dermatitis disease severity, while it was 
insignificant regarding the objective SCORAD. However, when atopic 
dermatitis children were classified according to the objective SCORAD 
index of severity into mild, moderate and severe, it was found that the mean 
serum level in the severe group was significantly higher than the 
corresponding values of the mild or the moderate group. OX40L levels did 
not correlate with serum total IgE or absolute eosinophils count. Serum total 
LDH levels correlated positively with each of the serum OX40L levels and 
the LSS and SCORAD indices of severity.  
Conclusions: Serum OX40L level is an objective reliable marker of atopic 
dermatitis severity in children. It may be useful for follow up and may help 
to improve research and management of this disease. Blockade of 
interactions between OX40 on Th2 cells and OX40L on activated dendritic 
cells using an OX40L-specific monoclonal antibody could represent a novel 
strategy for the treatment of atopic dermatitis.  
 
Keywords: Atopic dermatitis, LSS, OX40, OX40L, SCORAD, SSS, TNF. 














Faculty of Medicine, 










Mohamed Hesham M. 
Ezzat. 





Ezzat et al. 
16 
functional soluble proteins, as a consequence of 
either alternative mRNA splicing or proteolytic 
cleavage of the transmembrane protein1. 
OX40 ligand (OX40L) and OX40 are members 
of the TNF and TNFR super families respectively. 
OX40L (TNFSF4) was originally termed 
glycoprotein 34 kDa (GP34) whose expression on T 
cells was induced by the tax gene of human T cell 
leukemia virus-I-infected T cells. OX40L is a type 
II transmembrane glycoprotein that exists as a 
homotrimer. Human OX40L cDNA encodes a 183 
amino acid (AA) polypeptide with an N-terminal 
cytoplasmic domain (AA 1-23) and a C-terminal 
extracellular domain (AA 51-183). OX40L may be 
shed from the membrane and exist in a soluble 
form2. 
OX40 (CD134/TNFRSF4) is primarily known 
to be a T cell activation marker that is preferentially 
expressed by activated CD4+T cells, whereas 
OX40L is mainly expressed by antigen presenting 
cells, including activated dendritic cells, B cells, 
macrophages, and Langerhans cells, as well as by T 
cells and endothelial cells. Unlike another 
costimulatory molecule, CD28, which plays an 
important role in T cell priming, OX40-OX40L 
interactions have been shown to be crucial for T 
cell activation and survival and for the generation 
of memory T cells from activated effector T cells1. 
OX40L/OX40 interaction is important for 
mediating both Th1 and Th2 responses. A recent 
study has made a clear distinction in requirements 
for OX40L between the 2 types of responses. They 
proposed a determinant role for OX40L in 
promoting Th2 polarization and response of naive 
CD4+ T cells in the absence of IL-12, while in the 
presence of IL-12, OX40L served to increase Th1 
responses. OX40L-mediated polarization of T cells 
along the Th2 lineage was initiated by dendritic cell 
activated with the cytokine thymic stromal 
lymphopoietin (TSLP)3.  
Recent studies have indicated the critical 
involvement of OX40/OX40L interaction in the 
pathogenesis of a variety of immunologic 
abnormalities of inflammatory, autoimmune, 
infectious, allergic, and allotransplantation-related 
diseases. In particular, OX40L on vascular 
endothelial cells may play a role in inflammatory 
vasculitis. Blockade of OX40/OX40L interaction 
has been shown to prevent, cure, or ameliorate 
these diseases. In contrast, activation of OX40 is 
known to break an existing state of tolerance in 
malignancies, leading to a reactivation of antitumor 
immunity4. 
 
Recent advances in understanding the cellular 
and molecular mechanisms of atopy have shed light 
on potential targets for the development of new 
therapies for atopic diseases. Recent analyses of 
microarray experiments on TSLP-stimulated 
dendritic cells have shown that OX40L is strongly 
induced by TSLP. In vitro neutralization of OX40L 
activity was able to block TSLP-activated dendritic 
cells polarization of naive T cells5. Blockade of 
interactions between OX40 on Th2 cells and 
OX40L on TSLP-activated dendritic cells using an 
OX40L-specific monoclonal antibody, had 
inhibited Th2 cell-mediated immune responses in 
both mouse and nonhuman primate models of 
allergic inflammation. The results point to potential 
therapeutic approaches to targeting the cellular and 
molecular mechanism underlying OX40L-mediated 
allergic inflammation.  
The aforementioned data suggest that 
OX40/OX40L interaction probably play a 
significant role in T cell responses and immune 
regulation of various T cell mediated disorders. To 
our knowledge, no data could be cited in literature 
concerning OX40L levels in serum or in other 
biological fluid of atopic dermatitis children. 
Therefore, this case-controlled longitudinal study 
was done to explore the expression of OX40L in 
serum of atopic dermatitis children and to identify 
the clinical relevance of measuring serum OX40L 
to disease activity and severity. 
 
METHODS 
This follow-up, case-control study was conducted 
on 64 children as a stratified non-random sample; 
34 with atopic dermatitis and 30 healthy children, 
during the period from the first of February 2008 to 
the end of November 2008. All children were 
enrolled from the Pediatric Allergy and 
Immunology Unit, and Pediatric and Dermatology 
outpatient clinics of Ain Shams University 
Hospitals, Cairo. An informed consent was 
obtained from the parents or caregivers of each 
child before enrollment. 
Patients: Children with atopic dermatitis were 
diagnosed according to the criteria proposed by 
Hanifin and coworkers6. They were subjected to a 
detailed history taking and thorough clinical 
examination to exclude subjects with any 
concomitant diseases. The parents were subjected to 
a questionnaire concerning the precipitating 
factor(s). A possible cause was traced in 25 children 
being exposed to food allergens: egg (8), milk (7), 
banana (3), fish (3), and multiple food allergens (4). 
In 9 children, the cause was not clear. 
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•Assessment of the clinical severity of atopic 
dermatitis: For convenience, the severity was 
assessed according to four different scoring 
systems; the Leicester Sign Score (LSS), Simple 
scoring system of Costa (SSS), Scoring Atopic 
Dermatitis (SCORAD) index, and Objective 
SCORAD. 
 The severity in LSS is scored by 6 clinical fea-
tures (erythema, purulence, excoriation/crusting, 
dryness/scaling, cracking/fissuring, and 
lichenification) graded at 6 defined body sites on 
a scale of 0 (none) to 3 (severe) [LSS score range: 
0 to 108]7. 
 The SSS or Costa's score calculates the intensity 
of 10 signs and symptoms along with 
involvement of 10 different skin regions. The 
intensity criteria are: erythema, edema, vesicles, 
crusts, excoriation, scales, lichenification, 
pigmentation or depigmentation, pruritus and loss 
of sleep8. 
 The SCORAD index was used to evaluate the 
severity of eczema by combining 2 objective 
symptoms (extent and intensity of eczema) and 2 
subjective symptoms (pruritus and sleep loss) to a 
maximum score of 103 points9.  
 The Objective SCORAD is a modification of the 
SCORAD that excludes the subjective symptoms 
as pruritus and sleep loss, to minimize the errors 
caused by variability in patient's ages and 
backgrounds. A proposal for severity grading of 
atopic dermatitis by using only objective criteria 
is as follows: (mild atopic dermatitis: score < 15; 
moderate atopic dermatitis: score = 15-40, and 
severe atopic dermatitis: score >40)10. 
Controls: Thirty clinically healthy children with no 
history of atopy were included as a control group. 
They were subjected to general and systemic 
clinical examination to exclude any current illness. 
Exclusion criteria: 
1. All subjects (patients and controls) with clinical 
or laboratory evidences of parasitic or other 
concomitant systemic or dermatological illnesses 
were excluded from the study.  
2. Atopic dermatitis children were enrolled after 
exclusion of a past, current or family history of 
other atopic or allergic diseases such as atopic 
asthma, allergic rhinitis or allergic conjunctivitis. 
3. Atopic dermatitis patients receiving systemic 
corticosteroids or immunosuppressive therapy 
were excluded. Topical corticosteroids and 
antihistamines were stopped for at least 2 weeks 
before inclusion in the study. Only topical 
emollients were used. 
4. Control subjects were enrolled after exclusion of 
a past, current or family history of atopic or 
allergic diseases. 
5. Control subjects with peripheral blood 




At enrollment, all children with atopic dermatitis 
were clinically evaluated for the severity while 
presenting with atopic dermatitis flare, then 
sampled for OX40L assay. Patients were followed 
up till quiescence of the disease by symptomatic 
therapy (systemic and topical corticosteroids, 
immunosuppressive therapy and antihistamines 
were stopped for at least 2 weeks before sampling), 
when follow up blood samples were collected. 
Quiescence and response to treatment was checked 
by using the Physician's Global Assessment (PGA) 
score. The PGA is an overall assessment from 0 to 
5 of a patient's eczema, taking into consideration 
the quality and extent of lesions relative to the 
baseline assessment (0 = clear [100%], 1 = almost 
clear [90% to 99% improvement], 2 = marked 
improvement [50% to 89%], 3 = modest 
improvement [<50%], 4 = no change, and 5 = 
worse).  
Laboratory evaluation 
Blood sampling: Five ml of venous blood were 
collected under complete aseptic precautions and 
divided into 2 parts. Two ml were mixed with 
EDTA for blood counting. Sera were separated 
from the remaining three ml and were stored at        
-20°C for quantitative measurement of serum 
OX40L, total IgE and lactate dehydrogenase 
(LDH). Repeated thawing and freezing was 
avoided. Hemolyzed and lipemic samples were 
excluded. 
Study measurements: 
1-Complete blood count: The blood count was 
performed in every subject with the Coulter counter 
(Coulter MicroDiff 18, Fullerton CA, USA). The 
differential leukocytic counts were estimated 
manually form the blood film and expressed in 
absolute count values. Infants and children whose 
absolute eosinophils counts (AEC) exceeded the 
normal reference values for age were considered to 
have peripheral blood eosinophilia11. Blood 
sampling of all subjects was performed at the same 
time (10 am) to avoid diurnal variations in 
eosinophils counts. 
2-Serum total IgE: Serum total IgE was assayed in 
all subjects by quantitative enzyme immunoassay 
(BioCheck, Inc 323 Vintage Park Dr. Foster City, 
CA 94404). Results were expressed in IU/ml. 
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Owing to the variability of serum total IgE levels 
with age; we calculated the percentage of the 
subject’s actual level to the highest normal for 
age11. IgE levels used in the correlations were both 
the measured and the calculated percentage values. 
The serum total IgE level that exceeded the highest 
normal for age was considered elevated. 
3-Serum total lactate dehydrogenase (LDH) 
assay: Serum total LDH (U/L) was measured in the 
atopic dermatitis group only during flare and in the 
healthy subjects. LDH assay was performed on an 
automatic chemistry analyzer (Synchron CX5 
system, Beckman, Inc., Fullerton, California, USA). 
4-Stool and urine analysis: To exclude any 
parasitic infestations when suspected. 
5-Quantitative determination of serum OX40 
Ligand: The Quantikine OX40 Ligand 
immunoassay is a 4.5 hour solid-phase ELISA. 
Reagents were supplied by Quantikine® (R&D 
Systems, Inc. 614 McKinley Place N.E. 




All statistical analyses of the data were carried out 
using SPSS (Statistical Package for the Social 
Science) version 11 for Windows system. Data 
were statistically represented in terms of range and 
mean ± standard deviation (SD). As regards 
parametric data, Student's "t" test was used to 
compare between 2 groups, and ANOVA test (F-
value) to compare more than 2 groups. The relation 
between various numerical parameters was studied 
by the Pearson correlation coefficient (r) test with 
graphic representation using linear regression line; r 
value was considered weak if <0.5, moderate if 
ranged between 0.5-0.75 and strong if  >0.75. P 
value less than 0.05 was considered significant. 
 
RESULTS 
According to the SCORAD index of severity, 14 
(41%) of the studied patients had moderate atopic 
dermatitis and the remaining 20 patients (59%) had 
severe atopic dermatitis. With respect to the 
objective SCORAD index, 7 (20.5%) had mild 
atopic dermatitis, 13 (38.5%) had moderate atopic 
dermatitis and 14 (41%) had severe atopic 
dermatitis. When atopic dermatitis patients and 
controls were compared with respect to serum total 
LDH, serum total IgE levels and AEC, statistically 
significant higher values were detected in the 
former group (p < 0.05 for all) (table 1). 
Serum OX40L levels during atopic dermatitis 
flares ranged between 443 and 2041 pg/ml (mean ± 
SD = 1007 ± 241.5 pg/ml). After subsidence of 
acute attacks, there was a significant decrease in 
OX40L serum levels (range = 421-980 pg/ml; mean 
± SD = 699 ± 198.5 pg/ml (t = 0.78; p < 0.001). The 
healthy children had much lower serum levels 
(range = 37-242; mean ± SD = 176.6 ± 45.9 pg/ml) 
as compared to the patients’ data whether during 
flare (t = 1.3; p < 0.0001) or quiescence (t = 0.9; p < 
0.0001) (figure 1). 
There was no significant difference in the 
OX40L serum levels between male and female 
subgroups in atopic dermatitis patients and controls 
(p>0.05). Serum OX40L levels could not be 
correlated to age both in the patient and the control 
groups. 
As regards the indices of atopic dermatitis 
severity, there were significant positive correlations 
between serum OX40L levels and each of the LSS, 
SSS and SCORAD indices of severity (figure 2), 
while it was insignificant regarding the objective 
SCORAD. According to the objective SCORAD 
index of severity, we found that the mean serum 
OX40L level of the severe atopic dermatitis group 
and that of the moderate group were significantly 
higher than the corresponding values of the mild 
group. Only mild cases had statistically comparable 
values to those of controls (figure 3). 
There were no significant correlations between 
serum OX40L levels or the indices of atopic 
dermatitis severity and serum total IgE level or 
AEC in patients group. Serum total LDH levels 
correlated positively with each of the serum OX40L 
levels (r = 0.63; p<0.01) and the LSS (r = 0.43; 
p<0.05) and SCORAD (r = 0.54; p<0.05) indices of 
severity. 
 
Figure 1. Serum OX40L levels (pg/ml) in atopic 
dermatitis children during flare and quiescence in 
comparison to controls. 
*: Statistical significant difference as compared to controls 
(p < 0.0001) 
$: Statistical significant difference (flare versus quiescence; 
p < 0.001) 
 




Figure 2. Significant positive correlations between 
serum OX40L levels (pg/ml) and the Leicester Sign 
Score (LSS), Simple scoring system of Costa (SSS), 
and the SCORAD index of atopic dermatitis disease 
severity. 
 
Table 1. Demographic, clinical, and laboratory data 
of patients with atopic dermatitis during flare and of 
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(M:F) 20:14 18:12 
Leicester Sign  
Score (LSS) 
20-85 
54.82 (10.62) --- 
Simple Scoring  
System (SSS) 
10-63 
47.11 (8.89) --- 
Scoring Atopic  
Dermatitis (SCORAD) 
13-58 
36.15 (5.67) --- 
Objective SCORAD 9-45 24.89 (7.52) --- 


























Figure 3. Serum OX40L levels (pg/ml) in atopic 
dermatitis patients according to the objective 
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DISCUSSION 
The clinical assessment of atopic dermatitis is 
complicated by variability among investigators; 
therefore an objective laboratory marker might have 
a more precise basis for monitoring disease activity 
and severity, and for evaluating the success of 
treatment12. 
In this study, serum OX40L levels of atopic 
dermatitis patients were significantly elevated as 
compared to control subjects whether during flare 
or quiescence. This result probably reflects the up 
regulation of OX40L in atopic dermatitis, 
presenting a potentially useful marker for the 
presence of an atopic reaction. The significant drop 
in serum levels during quiescence not only signifies 
the potentiality of OX40L as an efficient marker of 
disease activity, but signifies also the importance of 
up regulation of OX40L by allergen exposure and 
microbial products in the initiation and 
amplification of the atopic skin response. 
The role of OX40/OX40L interaction during T-cell-
dendritic cell interaction in atopic dermatitis is to be 
elucidated. OX40L might represent an early trigger 
of the allergic immune cascade. Unlike another 
costimulatory molecule, CD28, which plays an 
important role in T cell priming, OX40/OX40L 
interactions during T-cell-dendritic cell interaction 
have been shown to be crucial for clonal expansion 
of antigen-specific T-cells, the generation, 
activation, and survival of T-cell and for the 
generation of memory T cells from activated 
effector T cells3. 
A large variety of laboratory measurements have 
been linked to disease activity and severity in atopic 
dermatitis, however most of them lack specificity 
(13). This study demonstrated that OX40L 
concentrations correlated positively with the indices 
of atopic dermatitis severity namely; LSS, SSS and 
SCORAD. 
The objective SCORAD index differentiated 
children with mild disease from those with 
moderate-to-severe disease, so that serum OX40L 
levels in subjects categorized as severe atopic 
dermatitis were significantly higher as compared to 
the moderate and mild groups. This substantiates 
the usefulness of OX40L as an objective marker of 
disease severity in atopic dermatitis. 
In the current study, there were no significant 
correlation between serum OX40L levels or the 
clinical indices of atopic dermatitis severity and 
serum total IgE levels in patients group. Laske and 
Niqqemann14 reported that serum IgE levels 
correlated with the degree of atopic dermatitis. Dhar 
et al.15 reported that IgE levels and absolute 
eosinophilic count were significantly higher in 
atopic dermatitis patients than in controls (as in the 
current study), however, IgE levels and the absolute 
eosinophilic count showed significant covariance 
with disease severity. They revealed that there was 
a non-homogeneous distribution of both IgE levels 
and absolute eosinophilic count which were 
reflected in the large range and higher standard 
deviation. They also found a significant association 
of these two parameters with a family history of 
atopic dermatitis only when both parents were 
affected. Also, they found a significant association 
of these two parameters with a history of bronchial 
asthma in patients with atopic dermatitis but not 
with allergic rhinitis. 
IgE levels are known to fluctuate throughout the 
disease stages. In this study, atopic dermatitis 
subjects were recruited at different stages of disease 
activity. Noteworthy, atopic dermatitis is not 
exclusively an IgE-mediated allergic disorder; 
where a fraction of atopic dermatitis patients had a 
normal or even decreased total IgE levels; these 
patients had a non-IgE associated type of the atopic 
eczema/dermatitis syndrome or the formerly called 
intrinsic type of atopic dermatitis. Although patients 
with atopic dermatitis frequently possess IgE 
antibody specific for inhalants or food allergens, it 
is not generally possible to induce skin lesions or 
atopic dermatitis by intradermal injection of the 
suspected allergen16. 
In the current study, there was no significant 
correlation between serum OX40L levels or the 
clinical indices of atopic dermatitis severity and 
absolute eosinophilic count. It is not clear whether 
OX40L may have a role in regulating the 
constitutive numbers of eosinophils in peripheral 
blood by inducing eosinophil chemotaxis. 
Moreover, the activity and the release of 
eosinophils were not always correlated with their 
count17. 
It was reported that the eosinophils counts roughly 
correlated with the disease severity, and that very 
high counts were common in severe cases of atopic 
dermatitis who had a personal or family history of 
respiratory atopy, while normal or moderately 
elevated counts were obtained in severe cases of 
'pure' atopic dermatitis who had neither a personal 
nor a family history of respiratory atopy18. Thus, it 
was suggested that disease severity and personal or 
family history of respiratory atopy are important 
factors in determining high blood eosinophils 
counts in atopic dermatitis. Since children recruited 
in this study had 'pure' atopic dermatitis without any 
history of other atopic disorders, the lack of 
correlation between the indices of atopic dermatitis 
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severity and the absolute eosinophils count could be 
expected. 
Therefore, it seems that atopic dermatitis severity 
scores and both IgE and eosinophils count represent 
different domains in atopic dermatitis assessment. 
They do not necessarily correlate well with each 
other and all three aspects must be individually 
evaluated to assess the well being of these patients. 
Serum total LDH levels of atopic dermatitis patients 
during flare were significantly higher than control 
values. LDH levels correlated positively with each 
of the serum OX40L levels and the LSS and 
SCORAD indices of severity. LDH was previously 
reported as a useful marker of severity of atopic 
dermatitis disease19. Elevated levels can be 
attributed to its release from damaged lesional 
epidermal cells into peripheral blood reflecting the 
extent of skin involvement and the degree of 
epidermal injury. 
In conclusion, the overexpression of OX40L in 
atopic dermatitis patients during flare and 
quiescence in comparison to healthy children 
signifies the importance of up regulation of OX40L 
by allergen exposure and microbial products in the 
initiation and amplification of the atopic skin 
response during T-cell-dendritic cell interactions 
presenting a potentially useful marker of the 
presence of an atopic response. The significant drop 
in serum levels during quiescence signifies the 
potentiality of OX40L as an efficient marker of 
disease activity. Moreover, the results of the current 
study namely the parallel association of OX40L 
with disease severity suggest a role for OX40L in 
the assessment of atopic dermatitis severity in 
children. 
Our findings with respect to serum OX40L 
expression in relation to atopic dermatitis disease 
clinical and laboratory variables must be regarded 
as preliminary, pending longitudinal confirmation 
on a larger sample. Little is known about the 
functional involvement of OX40/OX40L 
interactions during T-cell-dendritic cell interaction 
in atopic dermatitis. Its role in the etiopathogenesis 
is far from clear yet, and should be clarified. 
Further study of OX40L functions within the 
TNF/TNFR super families individually and their 
interplay should provide insights into the 
pathogenesis of atopic dermatitis, and might have 
great implications for treatment of severe 
recalcitrant atopic dermatitis. Moreover, additional 
studies are recommended to clarify whether 
blocking OX40L or neutralizing its receptor by 
various neutralizing agents could represent a novel 
strategy for the treatment of atopic dermatitis. 
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